Photo of Martin P. Schrama

Martin P. Schrama is an expert Civil Trial Attorney as certified by the Supreme Court of New Jersey. He is also the Chair and Co-Founder of the Stark & Stark Mass Tort Litigation practice, as well as a member of the firm’s Commercial Litigation and Intellectual Property practices.

On April 24, 2019, the second Case Management Conference (CMC) in the Valsartan Multidistrict Litigation (MDL) before Judge Kugler in Camden, New Jersey was conducted. As part of the agenda, the Court sought to finalize the leadership structure for plaintiffs and defendants. Accordingly, partner, Stefanie Colella-Walsh, has been named as one of the attorneys on Plaintiffs’ Steering Committee.

Continue Reading Stark & Stark Named to Plaintiffs’ Steering Committee in Valsartan Litigation

You have seen a lot of commercials and have probably been searching the internet for some straightforward explanations about Xeljanz Lawsuits.

Very simply, Xeljanz (aka tofacitinib) is a drug made by Pfizer used to treat arthritis. Because Xeljanz has to essentially suppress the patient’s immune system to treat arthritis inflammation, the drug has a lot of bad side effects that are clearly displayed on the drug’s label.

However, one of the side effects not specifically warned about is blood clots. A recent FDA safety alert has warned that Xeljanz, taken in certain doses, can cause an increased risk of blood clots in the lungs and death.


Continue Reading What Is the Deal With Xeljanz Lawsuits?

On April 17, 2019, Judge Sargus, who is overseeing the Bard Hernia Mesh MDL in the Southern District of Ohio, held a Case Management Conference. At the time of the conference, the Court noted that there were just over 1,700 cases filed in the MDL, with approximately 80-100 new cases being filed each week. The parties advised that the protocol and schedule for conducting various depositions were still being discussed, including the depositions of the treating physicians, corporate designees, and company witnesses. Paper discovery from defendants is also still being produced and reviewed by Plaintiffs’ leadership. Another conference is scheduled for early June.

Continue Reading Bard Hernia Mesh Litigation Continues in Federal and State Courts

Currently, there are more than 10,000 IVC filter cases filed across the country, in state and federal courts, with a majority being filed against manufacturers, Bard Medical and Cook Medical. IVC filters are small devices surgically implanted into the inferior vena cava in an effort to catch blood clots (where they should naturally dissolve) before they travel to the lungs, causing a potentially fatal pulmonary embolism. The Bard MDL (multidistrict litigation) is venued in the District of Arizona, while the Cook MDL is venued in the Southern District of Indiana. Additionally, lawsuits are being filed against Boston Scientific for its Greenfield Vena Cava Filter in Ohio; as well as Rex Medical and Argon Medical for their Option and Option Elite IVC Filters in Pennsylvania.

Continue Reading IVC Filter Cases Continue to Move Forward

On March 27, 2019, the initial Case Management Conference for the Valsartan MDL was held in the District of New Jersey before the Honorable Robert B. Kugler. At the time that the cases were consolidated before Judge Kugler, for pretrial purposes, in February 2019, there were approximately 40 cases filed, but we expect thousands of cases to be filed over the next couple years.

Continue Reading Initial Court Conference Kicks Off Valsartan Litigation in New Jersey

You have seen a lot of commercials and have probably been searching the internet for some straightforward explanations about Valsartan Lawsuits.

Very simply, Valsartan (aka Diovan) is part of a class of drugs, including Losartan (aka Cozaar) and Irbesartan (aka Avapro), that are used in different combinations to treat heart failure, high blood pressure and certain effects of diabetes. The Valsartan drugs basically block a natural chemical in the body called angiotensin II, which can constrict a patient’s blood vessels and cause hypertension.


Continue Reading What Is the Deal With Valsartan Lawsuits?

In May 2018, a class action, as well as multiple personal injury cases, were filed against Gilead Sciences, Inc. (Gilead), for claims surrounding the promotion of the manufacturer’s TDF HIV/AIDs drugs.

The allegations included:

  • Gilead’s marketing and distribution of the TDF drugs, when a safer alternative (TAF) was known;
  • Failure to adequately warn of the potential risks; and,
  • Misrepresentation of the drugs’ safety and efficacy.

Currently, Plaintiffs allege kidney and bone injuries as a result of their use of the TDF drugs.


Continue Reading HIV/AIDS Drug Litigation Moves Forward

We have already written about the thousands of Bard hernia mesh cases pending in Rhode Island state court moving swiftly towards bellwether trials. Not to be outdone, the federal Multidistrict Litigation (MDL) cases in the United States District Court for the Southern District of Ohio, before Judge Edmund A. Sargus, are heating up as well.

The MDL encompasses claims against C.R. Bard and its corporate subsidiary, Davol, based upon allegations that Bard’s polypropylene hernia mesh was defective and caused injuries to patients. Even though the MDL was formed in August 2018, the Court has already put together an aggressive procedure and schedule for bellwether cases.


Continue Reading Bard Hernia Mesh MDL Moving Quickly

You have seen a lot of commercials and have probably been searching the internet for some straightforward explanations about TDF drug and Truvada lawsuits.

Very simply, TDF is short for tenofovir disoproxil fumarate. It is an HIV drug marketed by Gilead. TDF drugs are sold under different brand names, such as:

  • Truvada (the most popular)
  • Atripla
  • Complera
  • Stribild
  • Symfi-Lo
  • Cimduo
  • Viread

Recent lawsuits across the country allege that TDF drugs have serious side effects, such as:


Continue Reading What is the Deal With TDF Drug and Truvada Lawsuits?

A California state jury found that pharmaceutical and manufacturing giant Johnson & Johnson’s talcum-based baby powder contained cancer-causing asbestos and caused a woman’s mesothelioma diagnosis. The jury awarded the woman a staggering $29.5 million.

Continue Reading Johnson & Johnson Slammed with $29.5M Verdict Over Baby Powder Suit